- Current report filing (8-K)
March 19 2012 - 6:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 16, 2012
Kensey Nash Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-34388
|
|
36-3316412
|
(State or other jurisdiction
of incorporation or organization)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
735 Pennsylvania Drive, Exton, Pennsylvania 19341
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (484) 713-2100
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 1.01.
|
Entry into a Material Definitive Agreement.
|
On March 16, 2012 Kensey Nash Corporation (the Company) entered into a settlement agreement (the Settlement Agreement) with St. Jude Medical, Inc. ( St. Jude
Medical), which resolves all disputes between the two companies relating to the Angio-Seal vascular closure device (the Angio-Seal device) licenses, as well as other related claims. Under the terms of the Settlement Agreement, the
Company will receive $39 million from St. Jude Medical, payable in 12 equal quarterly payments beginning March 31, 2012, in lieu of all future royalties for the Angio-Seal and all other related claims.
As part of the Settlement Agreement and forming Schedule D to it, the Company and St. Jude Medical entered into a new collagen supply agreement (the
2012 Collagen Supply Agreement), replacing and effectively extending the previous such agreement between the parties which was set to expire on December 31, 2012. Pursuant to the 2012 Collagen Supply Agreement, the Company will
continue to be the exclusive outside supplier of collagen for the Angio-Seal device through the contract term of December 31, 2017. In addition, the 2012 Collagen Supply Agreement expands the minimum orders to be provided over the contract term
to five million units.
The Settlement Agreement is filed as Exhibit 10.1 to this Form 8-K, and the foregoing descriptions of the agreement is
qualified in its entirety by reference to the full text of the agreement set forth in Exhibit 10.1 and hereby incorporated by reference herein.
Item 7.01
|
Regulation FD Disclosure
|
On
March 16, 2012 the Company issued a press release announcing that it entered into the Settlement Agreement and the 2012 Collagen Supply Agreement, as defined in Item 1.01 of this Current Report, and as a result, the Company updated its
earnings guidance for the quarters ending March 31, 2012 and June 30, 2012, its full fiscal year ending June 30, 2012, as well as preliminary top level guidance for its full fiscal year ending June 30, 2013. The press release is
included as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
The information in this Item 7.01 of this Current
Report (including Exhibit 99.1 hereto) shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
|
|
|
|
|
10.1
|
|
Confidential Settlement Agreement between Kensey Nash Corporation and St. Jude Medical Inc., dated as of March 16, 2012.*
|
|
|
99.1
|
|
Press Release of Kensey Nash Corporation dated March 16, 2012. (furnished herewith)
|
*
|
Portions of this exhibit were omitted and have been filed separately with the Securities and Exchange Commission pursuant to an application for confidential treatment
under Rule 24b-2 under the Securities Exchange Act of 1934 and Rule 406 under Securities Act of 1933.
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
KENSEY NASH CORPORATION
|
|
|
By:
|
|
/s/ Michael Celano
|
|
|
Michael Celano
|
|
|
Chief Financial Officer
|
Dated: March 19, 2012
3
Kensey Nash (NASDAQ:KNSY)
Historical Stock Chart
From May 2024 to Jun 2024
Kensey Nash (NASDAQ:KNSY)
Historical Stock Chart
From Jun 2023 to Jun 2024